Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its medical device subsidiary, Designer Diagnostics, has initiated a partnership with the U.S. Commercial Service to help build international sales of its diagnostic test kits.
“Partnering with the U.S. Commercial Service provides Designer Diagnostics with an incredible opportunity to build key relationships with international buyers of medical diagnostic equipment,” explained Neil Roth, President of Designer Diagnostics, Inc. “We will begin by focusing on geographic regions in Africa and South Asia where Tuberculosis and NonTuberculosis Mycobacterium have a higher level of occurrence,” he added.
The U.S. Commercial Service is a division of the U.S. Department of Commerce and is designed to provide American businesses with international market research data and introductions to international buyers and distributors. The Organization has offices in over 107 U.S. cities and in 145 U.S. Embassies and Consulates worldwide.
“This partnership will provide Designer Diagnostics with access to a group of international buyers that understand the significance of our improved test kit technology,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Not only are the Designer Diagnostics test kits faster, but they are also more cost effective compared to all other traditional methods. Additionally, they can be used in the field and stored in hostile environments, requiring no special handling or refrigeration,” he concluded.
In January, Designer Diagnostics announced the positive results of an in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing methods can take as long as 10 weeks to produce results, whereas Designer Diagnostics test kits showed similar results within 10 days.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The partnership with the U.S. Commercial Service should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.